Hyphens Pharma International Limited
138 Joo Seng Road, 3rd Floor, Singapore 368361
T: (65) 6338 8551 F: (65) 6338 8825 W: www.hyphens.com.sg
Co. Reg. No.: 201735688C

NEWS RELEASE

HYPHENS PHARMA INTERNATIONAL LIMITED MAKES STRONG LISTING DEBUT ON THE CATALIST BOARD OF THE SGX-ST

- ***Opening and closing prices of S$0.30 and S$0.275 per Share respectively, above Invitation Price of S$0.26 per Invitation Share***
- ***20.4 million Shares changed hands, representing 6.8% of the total issued and paid-up share capital of Hyphens Pharma International Limited***

Capitalised terms used herein, unless otherwise defined, have the meanings ascribed to them in the offer document of Hyphens Pharma International Limited registered by the Singapore Exchange Securities Trading Limited (acting as agent on behalf of the Monetary Authority of Singapore) on 11 May 2018.

Singapore, 18 May 2018 – Hyphens Pharma International Limited (凯帆药剂国际有限公司) (the "Company", and together with its subsidiaries, the "Group"), one of Singapore's leading specialty pharmaceutical and consumer healthcare groups, is pleased to announce that it commenced trading at 9.00 a.m. today on the Catalist Board of the Singapore Exchange Securities Trading Limited ("SGX-ST"), with an opening price of S$0.30, which is 15.4% above the Invitation Price of S$0.26 per Invitation Share.

Trading of the Shares remained active throughout the trading day and closed 5.8% above the Invitation Price at S$0.275. A total of 20.4 million Shares were traded today.

From Left to Right: ***Dr. Poon Thong Yuen****, Independent Director of Hyphens Pharma International Limited;* ***Mr. Heng Wee Koon****, Lead Independent Director of Hyphens Pharma International Limited;* ***Mr. Chan Kum Kong****, Head of Research & Products, SGX;* ***Mr. Lim See Wah****, Chairman, Executive Director and CEO of Hyphens Pharma International Limited;* ***Mr. Tan Chwee Choon****, Executive Director of Hyphens Pharma International Limited;* ***Mr. Tan Jeh Wuan****, Managing Director & Head, Capital Markets - Singapore, DBS Bank Ltd.;* ***Dr. Tan Kia King****, Non-Executive Director of Hyphens Pharma International Limited; and* ***Mr. Ng Eng Leng****, Independent Director of Hyphens Pharma International Limited*

Mr. Lim See Wah (林世华), Chairman, Executive Director and CEO of the Company said, “We are heartened by the robust trading performance and warm reception from the market on our debut. With our regional footprint, portfolio of internationally well-known specialty pharmaceutical products and proprietary range of products and brands, we are poised to tap significant synergies between our business segments as we enter our next phase of growth.”

The Company's Initial Public Offering (the "IPO" or the "Invitation") closed on 16 May 2018, with strong support from investors. The Public Offer Shares were approximately 152.0 times subscribed. The Company raised net proceeds of approximately S$13.5 million from the Invitation and the issuance of Cornerstone Shares to the three cornerstone investors, Nikko Asset Management Asia Limited, Qilin Asset Management Pte. Ltd., and Maxi-Harvest Group Pte. Ltd.

The Company's market capitalisation at closing was S$82.5 million, based on the Company's share capital immediately after the completion of the Invitation and the issuance of the Cornerstone Shares.

DBS Bank Ltd. is the Sponsor, Issue Manager, Underwriter and Placement Agent in connection with the IPO.

- Ends -

About Hyphens Pharma International Limited

Hyphens Pharma International Limited and its subsidiaries (the "Group") is one of Singapore's leading specialty pharmaceutical and consumer healthcare groups leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in five ASEAN countries, namely, Singapore, Vietnam, Malaysia, Indonesia and the Philippines, supplemented by a marketing and distribution network covering five additional jurisdictions, namely, Hong Kong, Myanmar, Brunei, Cambodia and Oman. Singapore is the Group's regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based.

The Group's core business comprises the following segments: specialty pharma principals, proprietary brands, and medical hypermart and digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.

For more information, please visit http://www.hyphens.com.sg/

ISSUED ON BEHALF OF	:	Hyphens Pharma International Limited
BY	:	Citigate Dewe Rogerson Singapore Pte Ltd
		55 Market Street
		#02-01
		SINGAPORE 048941
CONTACT	:	Ms Chia Hui Kheng / Mr Aaron Ng
		at telephone
DURING OFFICE HOURS	:	6534-5122
EMAIL	:	huikheng.chia@citigatedewerogerson.com/
		aaron.ng@citigatedewerogerson.com

May 18, 2018

Important Notice

This announcement does not constitute an offer, invitation to purchase or subscribe for or solicitation of securities in Singapore or any other jurisdiction nor should it or any part of it form the basis of, or be relied upon in any connection with, any contract or commitment whatsoever.

The value of the Shares and the income derived from them may fall as well as rise. Shares are not obligations of, deposits in, or guaranteed by, the Company or the Sponsor, Issue Manager, Underwriter and Placement Agent or any of their respective affiliates. An investment in the Shares is subject to investment risks, including the possible loss of the principal amount invested. Listing of the Shares on the SGX-ST does not guarantee a liquid market for the Shares.

This announcement has been prepared by the Company and its contents have been reviewed by DBS Bank Ltd. (the "Sponsor") for compliance with the Rules of Catalist. The Sponsor has not independently verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact persons of the Sponsor are Heng Mui Mui, Managing Director and Kelvin Wong, Vice President at 12 Marina Boulevard Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone +65 6878 8888.